Group 1 - The company, Da An Gene, reported that as of September 30, 2025, the total number of shareholders is approximately 140,000 [1]

Core Insights - The Chinese epigenetics industry has made significant progress in recent years, becoming a research hotspot in the life sciences field, with a market size projected to reach approximately 4.396 billion yuan in 2024, reflecting a year-on-year growth of 62.27% [1][8][10] - The growth is driven by advancements in technologies such as high-throughput sequencing and single-cell sequencing, leading to broader applications in disease diagnosis, treatment, basic research, and crop breeding [1][8][10] Industry Overview - Epigenetics studies heritable changes in gene expression that do not involve changes to the underlying DNA sequence, focusing on the regulation of genes at the transcriptional level [2][4] - Key epigenetic modifications include DNA methylation, histone modification, chromatin remodeling, and RNA modifications [2][4] Industry Development History - The exploration phase of epigenetics in China occurred from the 1940s to 1970s, with significant setbacks due to political influences [4][5] - The initial development phase from the 1980s to 1990s saw the introduction of international genetic theories and the beginning of research into DNA methylation and histone modifications [5][6] - From 2000 to 2010, rapid development occurred, with China participating in the Human Epigenome Project and launching significant research initiatives [6][8] - Since 2010, the industry has matured, with increased international collaboration and applications in disease mechanisms, agriculture, and environmental adaptation [6][8] Industry Value Chain - The upstream of the epigenetics industry includes raw materials such as biological reagents and nucleic acid extraction kits, as well as scientific equipment like high-throughput sequencers and bioinformatics software [7] - The midstream focuses on research and development, while the downstream applications span medical fields (e.g., cancer early screening and precision treatment) and agriculture [7] Market Size - The Chinese epigenetics market is expected to reach approximately 4.396 billion yuan in 2024, with a year-on-year growth of 62.27%, driven by technological advancements and increasing market demand [1][8][10] Industry Trends - Technological innovation and multi-omics integration are driving advancements in precision medicine, with AI and single-cell sequencing enhancing early cancer screening capabilities [12][13] - Applications of epigenetics are expanding into agriculture, environmental science, and health management, demonstrating versatility across various fields [13] - Policy support and market expansion are fostering a comprehensive innovation ecosystem, with increased gene testing coverage and collaboration in international research initiatives [14]

Core Viewpoint - Guangzhou Da'an Gene Co., Ltd. has developed the first nucleic acid test kit for Chikungunya virus in China, which has recently received approval from the National Medical Products Administration, marking a significant advancement in rapid disease identification and control [1] Group 1: Product Development and Approval - The Chikungunya virus nucleic acid test kit is designed for qualitative detection of the virus in serum samples from suspected cases [1] - The approval process for the test kit took less than one month, showcasing the efficiency of the regulatory framework in Guangzhou [1] Group 2: Regulatory Support and Efficiency - The Huangpu District Market Supervision Administration facilitated the rapid approval by coordinating with the Guangdong Provincial Medical Device Quality Supervision and Inspection Institute to include the test kit in an emergency inspection channel, completing all testing within a week [1] - Enhanced communication with higher-level regulatory bodies was established to streamline the product review and approval process [1]

证券代码：002030 证券简称：达安基因 公告编号：2025-052 广州达安基因股份有限公司 关于取得一个医疗器械注册证的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督管 理局颁发的医疗器械注册证一个，具体为： 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 特此公告。 广州达安基因股份有限公司 董 事 会 2025 年 9 月 29 日 医疗器械名称：人类 ALDH2 基因分型检测试剂盒（PCR-荧光探针法），注 册证编号：国械注准 20253402003。有效期自批准之日起至 2030 年 9 月 28 日。 预期用途：本试剂盒适用于体外定性检测人全血样本基因组 DNA 中 ALDH2 基 因 G1510A（rs671）位点多态性。 ...

Core Viewpoint - The first nucleic acid test kit for Chikungunya virus has been approved for sale in Guangdong, China, with a production capacity that can be scaled up to 10 million tests per day within a month to meet demand [1] Company Summary - Da An Gene has received a medical device registration certificate from the National Medical Products Administration for the Chikungunya virus nucleic acid test kit, which is valid until September 24, 2030 [1] - The test kit is designed for the qualitative detection of Chikungunya virus nucleic acid in serum samples from suspected cases of Chikungunya fever and for differential diagnosis [1]

Core Points - The company has obtained a medical device registration certificate for a Chikungunya virus nucleic acid detection kit, which is intended for in vitro qualitative detection of the virus in suspected cases [1][2] - The registration certificate is valid until September 24, 2030, and the product is currently in the market development stage, indicating potential uncertainty in market demand [2][3] Group 1 - The medical device name is Chikungunya Virus Nucleic Acid Detection Kit (Fluorescent PCR Method), with registration number 20253401955 [1] - The kit is designed for detecting Chikungunya virus nucleic acid in serum samples from suspected cases and should be used in accordance with relevant guidelines [1][2] - The company emphasizes that the test results are for clinical reference only and should not be the sole basis for clinical diagnosis [1] Group 2 - The acquisition of this registration certificate enriches the company's product portfolio and expands its application areas [2] - The company advises investors to be aware of investment risks due to the current uncertainty in market demand for the new product [2]

Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

Core Viewpoint - The company, DaAn Gene (002030.SZ), has recently obtained a medical device registration certificate from the National Medical Products Administration for a new product, the Chikungunya Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) [1] Group 1 - The medical device registration certificate number is 国械注准20253401955 [1]

Core Viewpoint - DaAn Gene has received a medical device registration certificate from the National Medical Products Administration for a Chikungunya virus nucleic acid detection kit, which is valid until September 24, 2030 [1] Company Summary - The newly approved kit is designed for the qualitative detection of Chikungunya virus nucleic acid in serum samples from suspected cases of Chikungunya fever and for differential diagnosis [1]

Core Viewpoint - The company, DaAn Gene, has recently obtained a medical device registration certificate from the National Medical Products Administration for a new product, the Chikungunya virus nucleic acid detection kit (fluorescent PCR method) [1] Group 1 - The medical device is officially registered under the certificate number: Guo Xie Zhu Zheng 20253401955 [1]